← Leaderboards
Inga Peter
Tufts Medical Center
$17,466,985
Attributed
$25,595,433
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,611,296 · 13
By mechanism
R01$17,328,585 · 7
P01$9,497,838 · 3
KL2$5,002,924 · 1
R21$465,125 · 1
P20$316,824 · 1
Top collaborators
- Heidi M. Crane17 shared
- Patrick James Drew5 shared
- Ethylin Wang Jabs5 shared
- Reuben H. Kraft5 shared
- Joan T Richtsmeier5 shared
- Paul A Romitti5 shared
- Robert J Devita3 shared
- Ihor R Lemischka3 shared
Most similar at Tufts Medical Center
Same institution · by research overlap
- Bradford A Navia$14,039,936
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortPathway InteractionsGenesGeneticPathogenesisBiologicalPhenotypePharmaceutical PreparationsResponseGenetic VariantClinical DataBaseValidationComplexLinkAffectRisk FactorsSiteFutureVariantChronicInflammationGenomicsAntiretroviral Therapy
Grant awards (50)
Institutional Career Development Core$1,243,549
KL2 · FY2025 · TR · contact PI
Clonal hematopoiesis, epigenetic changes, social determinants of health, and behavioral risk factors as predictors of accelerated aging in HIV$703,644
R01 · FY2025 · AG · contact PI
The study of Eicosanoids as Novel Inflammatory Mediators of CVD in Men and Women with HIV$682,957
R01 · FY2025 · HL
Institutional Career Development Core$1,253,125
KL2 · FY2024 · TR · contact PI
The study of Eicosanoids as Novel Inflammatory Mediators of CVD in Men and Women with HIV$683,202
R01 · FY2024 · HL
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$383,980
R01 · FY2024 · DK · contact PI
Institutional Career Development Core$1,253,125
KL2 · FY2023 · TR · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$823,490
R01 · FY2023 · HG · contact PI
The study of Eicosanoids as Novel Inflammatory Mediators of CVD in Men and Women with HIV$719,345
R01 · FY2023 · HL
Genetic Predisposition and Pharmacogenomics of HIV-Associated Cognitive Impairment$400,773
R01 · FY2023 · HG · contact PI
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$399,978
R01 · FY2023 · DK · contact PI
Institutional Career Development Core$1,253,125
KL2 · FY2022 · TR · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$823,609
R01 · FY2022 · HG · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$780,507
R01 · FY2022 · DA
Preclinical Validation of Novel Gut-Restricted LRRK2 Inhibitors as Therapeutic Leads for IBD$399,978
R01 · FY2022 · DK · contact PI
Effect of Maternal IBD, Microbiome and Early Life Events on the Bacterial Colonization and Mucosal Immunity in the Offspring$211,250
R21 · FY2022 · DK · contact PI
Investigating the relationship of genetic, microbial, and intestinal inflammatory biomarkers in PD pathogenesis$158,855
P20 · FY2022 · NS · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$1,042,014
R01 · FY2021 · DA
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$827,529
R01 · FY2021 · HG · contact PI
Effect of Maternal IBD, Microbiome and Early Life Events on the Bacterial Colonization and Mucosal Immunity in the Offspring$253,875
R21 · FY2021 · DK · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$159,270
R01 · FY2021 · DA
Investigating the relationship of genetic, microbial, and intestinal inflammatory biomarkers in PD pathogenesis$157,969
P20 · FY2021 · NS · contact PI
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$824,847
R01 · FY2020 · HG · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$790,896
R01 · FY2020 · DA
Craniosynostosis Network$1,131,731
P01 · FY2019 · HD
Pharmacogenomics and Systems Pharmacology Approaches to Toxicity, Tolerability, and Comorbidities Associated with Modern Antiretroviral Therapies$839,731
R01 · FY2019 · HG · contact PI
Genes, substance use, and HIV outcomes in people living with HIV across the US$790,896
R01 · FY2019 · DA
Project II: Genomic Approaches to Coronal Nonsyndromic Craniosynostosis$256,638
P01 · FY2019 · HD · contact PI
Core B: Molecular/Analytic Core$225,346
P01 · FY2019 · HD · contact PI
Craniosynostosis Network$1,321,910
P01 · FY2018 · HD
Genes, substance use, and HIV outcomes in people living with HIV across the US$830,691
R01 · FY2018 · DA
Project II: Genomic Approaches to Coronal Nonsyndromic Craniosynostosis$273,477
P01 · FY2018 · HD · contact PI
Core B: Molecular/Analytic Core$227,662
P01 · FY2018 · HD · contact PI
Craniosynostosis Network$1,596,474
P01 · FY2017 · HD
Genomic approaches to cardiometabolic risk and treatment in HIV$759,333
R01 · FY2017 · HL · contact PI
Core B: Molecular/Analytic Core$349,140
P01 · FY2017 · HD · contact PI
Project II: Genomic Approaches to Coronal Nonsyndromic Craniosynostosis$246,804
P01 · FY2017 · HD · contact PI
Craniosynostosis Network$1,442,127
P01 · FY2016 · HD
Genomic approaches to cardiometabolic risk and treatment in HIV$714,351
R01 · FY2016 · HL · contact PI
Core B: Molecular/Analytic Core$344,346
P01 · FY2016 · HD · contact PI
Project II: Genomic Approaches to Coronal Nonsyndromic Craniosynostosis$121,598
P01 · FY2016 · HD · contact PI
Genomic approaches to cardiometabolic risk and treatment in HIV$700,862
R01 · FY2015 · HL · contact PI
Craniosynostosis Network$1,523,621
P01 · FY2014 · HD
Genomic approaches to cardiometabolic risk and treatment in HIV$709,888
R01 · FY2014 · HL · contact PI
Core B: Molecular/Analytic Core$348,239
P01 · FY2014 · HD · contact PI
Project II: Genomic Approaches to Coronal Nonsyndromic Craniosynostosis$88,725
P01 · FY2014 · HD · contact PI
Genetic Markers of GIK Effect in Acute Coronary Syndrome in the IMMEDIATE Trial$377,569
R01 · FY2012 · HL · contact PI
Genetic Markers of GIK Effect in Acute Coronary Syndrome in the IMMEDIATE Trial$377,987
R01 · FY2011 · HL · contact PI
Genetic Markers of GIK Effect in Acute Coronary Syndrome in the IMMEDIATE Trial$375,186
R01 · FY2009 · HL · contact PI
Genetic Markers of GIK Effect in Acute Coronary Syndrome in the IMMEDIATE Trial$406,072
R01 · FY2007 · HL · contact PI